BILTHOVEN, the Netherlands,
Feb. 23, 2021 /PRNewswire/
-- Intravacc, a world leader in translational research
and development of vaccines, today announced the formation of a
Scientific Advisory Board ("SAB"), chaired by Intravacc's Chief
Scientific Officer Virgil Schijns
and further comprising scientific leaders in the fields
of vaccinology, infectious diseases and oncology. Intravacc's
SAB will be consulted to help define the proper vaccine strategies
and solutions to establish an impact on public health supported by
convincing scientific clinical data. The SAB will also advise on
the company's research strategy and approaches to optimize therapy
effectiveness and added value.
Prof. Dr. Virgil Schijns,
Intravacc's Chief Scientific Officer, commented:
"We are delighted to launch our
Vaccine Scientific Advisory Board with these impressive scientists
as charter members. We view their agreement to advise us on the
development of our groundbreaking multiplatform vaccines as a vote
of confidence in our technology. This distinguished group of
scientific leaders can provide Intravacc with highly valued counsel
and guidance as we continue expanding our contract development and
manufacturing franchise, including our pioneering endeavors
in therapeutic vaccines".
Prof. Dr. Evelien Smits is
research professor in tumor immunology and cancer immunotherapy at
the University of Antwerp,
Belgium. She is researching how the immune system of cancer
patients can be provided with the necessary weapons to win the
battle against cancer cells.
Dr. Harry Flore is
Chairman of the Supervisory Board of HAL Allergy Holding of Leiden,
the Netherlands - one of
Europe's top players in the field
of allergen immunotherapy, and a world leader in the production of
modified allergen extracts for both therapeutic and diagnostic
purposes. He is also active in HALIX, a CDMO, specializing in cell
culture-based pharmaceutical production.
Prof. Dr. Anke
Huckriede is Professor of Vaccinology at the University
of Groningen, the Netherlands, and
is affiliated with the University Medical Center Groningen.
Huckriede's research activities are aimed at vaccine development,
with a focus on rational vaccine design. Her work on (influenza)
vaccines focuses, among other things, on developing in vitro
techniques for vaccine evaluation and understanding the effects of
pre-existing immunity on responses to vaccination.
Dr. Paul Wichgers Schreur
is a senior scientist in the field of arbovirology at Wageningen
Bioveterinary Research (WBVR). Using techniques like
reverse-genetics, single-molecule microscopy, and bacterial
superglue he studies the infection cycle of bunyaviruses and uses
this knowledge to (co)develop therapeutic antibodies and
vaccines.
Dr. Marien de Jonge is
Associate Professor at Radboud University Medical Center, acting as
Head of the Pediatric Infectious Diseases Section. He has more than
15 years of experience in both academic research and industrial
R&D, mainly in the field of vaccine development and infectious
diseases.
Dr. Paul Oostvogel M.D. is medical
microbiologist. He has been involved in the Polio Eradication
Initiative from the start in 1989. He retired in 2019 as head of
the Public Health Laboratory of the Public Health Service (GGD)
Amsterdam.
Dr. Jan Groen, Intravacc's
CEO, said:
"I am delighted to have
such an accomplished and diverse group of scientific, clinical and
industry experts as inaugural members of our Scientific Advisory
Board. Their expertise will ensure our activities remain firmly
based on sound science and will help us discover new opportunities
for vaccine innovation.''
About Intravacc
Dutch Intravacc, located at Utrecht Science Park Bilthoven, is a
leading global contract developer and producer of innovative
vaccines against infectious diseases. As an established independent
CDMO organization with over 100 years of experience in the
development and optimization of vaccines and vaccine technologies,
Intravacc has transferred its technology related to polio vaccines,
measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines
around the world. Around 40% of childhood disease vaccines are
based on Intravacc's technology. Intravacc offers a wide range of
expertise for independent vaccine development, from concept to
Phase I/II clinical studies for partners around the world,
including universities, public health organizations (WHO, Bill
& Melinda Gates Foundation), biotech and pharmaceutical
companies.
For more information, visit www.intravacc.nl
Contacts:
Intravacc
Dr. Jan
Groen, CEO
P: +31 30 7920 454
Mirjam Hartman, Media
relations
P: +31 6 115 969 94
E: press.office@intravacc.nl
LifeSpring Life Sciences Communication, Amsterdam
Leon
Melens
P: +31 6 538 16427
E: lmelens@lifespring.nl
Logo -
https://mma.prnewswire.com/media/1334670/Intravacc_Logo.jpg